The National Cancer Center (NCC) Japan, Precision Medicine Asia (PREMIA), and Paradigm Health have partnered to launch LC-SCRUM-CD, a nationwide clinical trial network for cancer research in Japan.
The collaboration will leverage LC-SCRUM-Asia's network of 150+ hospitals for cancer genomic screening. PREMIA will manage the data platform, and Paradigm will provide its end-to-end clinical trial platform. The partnership aims to increase global pharmaceutical-sponsored trials in Japan while reducing the operational burden on healthcare providers.
The initiative builds upon NCC Hospital East's clinical trial capabilities, which currently run over 500 studies annually. It will enable more efficient patient selection for clinical trials through the integration of genetic analysis results and clinical data.
Analyst QuickTake: This is the second partnership Paradigm has established in Japan. Earlier this year, Paradigm partnered with Fujitsu , a global technology company, to improve clinical trials and address drug loss in Japan. The company appears to be continuing its global expansion strategy, focusing on Japan.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.